There is one clinical trial.
To evaluate the safety and efficacy of humanized Meplazumab for Injection in patients infected by 2019-nCoA.
Description: Virological clearance rate using Real-Time PCR in upper and/or lower respiratory tract samples at day 3, day 7 and day 14 respectively.Measure: 2019 nCoV nucleic acid detection Time: 14 days
Description: Time (days) from initiation of Meplazumab treatment until normalization of body temperature (≤37℃ axilla)Measure: Recovery of body temperature Time: 14 days
Description: Time (days) from initiation of Meplazumab treatment until normalization of resting respiratory rate (≤24/min)Measure: Recovery of resting respiratory rate Time: 14 days
Description: Time (days) from initiation of Meplazumab treatment until normalization of SPO2 (>94%)Measure: Recovery of SPO2 Time: 14 days
Description: Rate of lung imaging recoveryMeasure: Chest CT / chest film changes Time: 28 days
Description: Rate of PaO2 / FiO2 recoveryMeasure: PaO2 / FiO2 Time: 14 days
Description: Days to reach the isolation release standardMeasure: Time to reach the isolation release standard Time: 28 days
Description: Rate of CRP, D-Dimer test recoveryMeasure: Changes of inflammatory immune status Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports